MMA
TTRX

Miracle Mile Advisors’s Turn Therapeutics TTRX Stock Holding History

Miracle Mile Advisors’s Portfolio TTRX Stock Details TTRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$117K Hold
16,000
– – ﹤0.01% 994
2026
Q1 		$51.2K Hold
16,000
– – ﹤0.01% 887
2025
Q4 		$63K Buy
+16,000
New +$66.7K ﹤0.01% 857

Other funds holding TTRX

SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
DI
DDFG Inc Thousand Oaks, California $504M AUM 18.61% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BA
Bridgewater Advisors New York $1.83B AUM 22.9% 1-Year Est. Return
AWA
Aaron Wealth Advisors Chicago, Illinois $1.97B AUM 36.91% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $1.07B AUM 26.86% 1-Year Est. Return

Miracle Mile Advisors's TTRX Position: Q2 2026 in Review

Miracle Mile Advisors held its Turn Therapeutics (TTRX) position steady in Q2 2026 at 16,000 shares worth $117K. The position accounts for ﹤0.01% of the portfolio, ranked #994.

Miracle Mile Advisors first reported a position in TTRX in Q4 2025 and has held it in 3 quarters since. 29 funds tracked by Wall St. Rank hold TTRX as of Q2 2026.

  • Miracle Mile Advisors held 16,000 shares of Turn Therapeutics worth $117K as of Q2 2026.
  • Miracle Mile Advisors left its Turn Therapeutics share count unchanged in Q2 2026.
  • Turn Therapeutics made up ﹤0.01% of Miracle Mile Advisors's portfolio in Q2 2026, its #994 holding.
  • Miracle Mile Advisors first reported a position in Turn Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 29 funds tracked by Wall St. Rank held Turn Therapeutics as of Q2 2026.

Based on Miracle Mile Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.